In addition to surgery and chemoradiotherapy, the recent advances in endocrine and targeted therapies have made them more prominent in individual comprehensive therapy of breast cancer, which benefits the majority of patients with hormone‐dependent or HER‐2 positive breast cancer.3, 4. Here, ERBB2 is linked to breast cancer.